Table 1.
Susceptibility of XMRV and HIV-1 to reverse transcriptase inhibitors.
| Inhibitor classb | Inhibitorc | EC50 (μM)a | ||
|---|---|---|---|---|
| HIV-1NL4-3 | XMRVVP62+LtatSNd | XMRV22Rv1+LtatSNd | ||
| NRTI | AZT | 0.10 ± 0.05 | 0.12 ± 0.03 (1) | 0.06 ± 0.02 (1) |
| AZddG | 0.71 ± 0.01 | 1.1 ± 0.1 (2) | 2.7 ± 0.7 (4) | |
| AZddA | 2.0 ± 0.9 | 1.6 ± 0.4 (1) | 3.2 ± 1.2 (2) | |
| tenofovir | 3.5 ± 0.9 | 5.8 ± 3.2 (2) | 5.3 ± 3.8 (2) | |
| adefovir | 14 ± 2 | 9.5 ± 3.7 (1) | 7.0 ± 0.8 (0.5) | |
| D4T | 0.99 ± 0.53 | 34 ± 22 (34) | 13 ± 1 (13) | |
| ddI | 1.79 ± 0.04 | 43 ± 23 (24) | 43 ± 12 (24) | |
| abacavir | 3.6 ± 1.9 | 94 ± 54 (26) | 66 ± 39 (18) | |
| 3TC | 0.35 ± 0.07 | > 40 (> 100) | > 40 (> 100) | |
| FTC | 0.059 ± 0.041 | > 40 (> 100) | > 40 (> 100) | |
| NNRTI | efavirenz | 0.005 ± 0.002 | > 1 (> 200) | > 1 (> 200) |
| nevirapine | 0.22 ± 0.07 | > 4 (> 18) | > 4 (> 18) | |
| PPi analog | PFA | 126 ± 93 | > 400 (> 3) | > 400 (> 3) |
a EC50 values were measured in MAGIC-5A cells as described in Methods and are the means ± standard deviation from two or more independent experiments. Numbers in parentheses indicate the fold change in EC50 relative to HIV-1NL4-3. Values shown in bold are significantly different from the corresponding values for HIV-1NL4-3 (p < 0.05, ANOVA with Tukey's multiple comparison test).
b NRTI, nucleoside reverse transcriptase inhibitor. NNRTI, non-nucleoside reverse transcriptase inhibitor. PPi analog, pyrophosphate analog.
c See Abbreviations for drug names.
d XMRV-pseudotyped LtatSN virus. See text for details.